News
IntrinsiQ Launches New Pharmaceutical Oncology Reporting
WALTHAM, Mass.-(Business Wire)-February 13, 2008 - IntrinsiQ, LLC, the expert source for clinical oncology insight, today launches a new reporting capability for pharmaceutical market research and clinical trial teams: IntelliCost, which pinpoints the dollar value of tumor market opportunities and benchmarks pricing for oncology therapies.
For the first time, pharmaceutical oncology teams will have actionable insight into patient populations and the drugs doctors are prescribing, cross referenced with a "dollarized" value of specific markets. IntelliCost provides new ability to:
— assess the real cost of therapy by tumor, metastatic line of therapy and regimen
— shape clinical trials for success based on clear understanding of the current cost of potential partner therapies
— perform cost-benefit analysis to determine how the addition of supportive care agents drive up the cost of completed therapy
"Pharmaceutical companies face immense pressure to develop breakthrough drugs and recoup sizeable up-front investments in R&D - revenue that drives research into the next round of therapies," said Jeff Forringer, general manager of IntrinsiQ's pharmaceutical data division. "IntelliCost helps researchers target the right price for every therapy - for unimpeachable go-to-market plans."
IntelliCost expands on and integrates with IntrinsiQ's current reporting that's based on real-time data collected from IntelliDose, IntrinsiQ's flagship clinical oncology software. IntelliDose manages and tracks chemotherapy administrations from over 500 oncologists, creating an up-to-the-minute record of more than 128,000 drug administrations provided monthly to 19,500 individual patients.
Available now, IntelliCost is an additional reporting service to clients' current IntrinsiQ subscriptions. The data is updated monthly for long-term visibility and tracking.
About IntrinsiQ
IntrinsiQ, LLC is the leading provider of medical oncology workflow solutions and the premier source of US oncology data and analysis. Each month, IntrinsiQ's market leading software application, IntelliDose(R), captures the treatment decisions and details from more than 500 oncologists, for more than 19,500 unique patients, and regarding more than 128,000 drug administrations. The IntrinsiQ database is unrivaled in accuracy, detail and timeliness of information about the medical oncology care process. This database is the foundation of products and services that uniquely address the business information needs of pharmaceutical product managers, market researchers and financial analysts. For more information, please visit www.intrinsiq.com.
Search Our News Using Google Search
Can't find what you want? Try using Google:
